Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
rCMu0ccgswRCgcKD
